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Abstract
Background: SSeCKS is a major protein kinase C substrate with kinase scaffolding and metastasis-
suppressor activity whose expression is severely downregulated in Src- and Ras-transformed
fibroblast and epithelial cells and in human prostate, breast, and gastric cancers. We previously used
NIH3T3 cells with tetracycline-regulated SSeCKS expression plus a temperature-sensitive v-Src
allele to show that SSeCKS re-expression inhibited parameters of v-Src-induced oncogenic growth
without attenuating in vivo Src kinase activity.
Methods: We use cDNA microarrays and semi-quantitative RT-PCR analysis to identify changes
in gene expression correlating with i) SSeCKS expression in the absence of v-Src activity, ii)
activation of v-Src activity alone, and iii) SSeCKS re-expression in the presence of active v-Src.
Results: SSeCKS re-expression resulted in the attenuation of critical Src-induced proliferative and
pro-angiogenic gene expression including Afp, Hif-1α, Cdc20a and Pdgfr-β, and conversely, SSeCKS
induced several cell cycle regulatory genes such as Ptpn11, Gadd45a, Ptplad1, Cdkn2d (p19), and
Rbbp7.
Conclusion:  Our data provide further evidence that SSeCKS can suppress Src-induced
oncogenesis by modulating gene expression downstream of Src kinase activity.
Background
SSeCKS, originally identified as a transcriptionally-sup-
pressed gene in v-src and ras-transformed rodent fibrob-
last cells [1], is the orthologue of human GRAVIN/
AKAP12 gene that encodes a kinase-scaffolding protein
[2] that is targeted as an autoantigen in some cases of
myasthenia gravis [3]. SSeCKS/Gravin/AKAP12 expres-
sion is severely downregulated in human prostate, breast
and gastric cancer, partially relating to the mapping of the
human gene to 6q24-25.1 [4], a cancer deletion hotspot
[5]. Re-expression of SSeCKS to physiologic levels in Src-
or Ras-transformed fibroblasts or epithelial prostate can-
cer cells suppresses morphological transformation,
anchorage- and growth factor-independent proliferation,
and metastatic potential, while restoring normal actin-
based cytoskeletal architecture and cell-cycle controls on
cyclin D1 expression [4,6,7]. SSeCKS also seems to control
the blood-brain barrier by suppressing astrocyte-
expressed vascular endothelial growth factor (VEGF) dur-
ing the switch to normoxic conditions after birth [8]. A
recent study indicates that the ability of SSeCKS to sup-
press lung metastasis formation by MatLyLu prostate can-
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cer cells correlates with its suppression of VEGF 165 and
121 isoforms [9]. Interestingly, SSeCKS does not grossly
alter the Src-mediated tyrosine phosphorylation of cellu-
lar substrates in vivo [6], strongly suggesting that SSeCKS
suppresses tumorigenicity by re-establishing controls on
downstream cytoskeletal and signaling pathways. How-
ever, it remains unclear which pathways are regulated by
SSeCKS during tumor or metastasis suppression.
In this report, we analyzed how SSeCKS re-expression
affects v-Src-induced oncogenic gene expression patterns
using oligonucleotide microarrays and semi-quantitative
RT-PCR techniques. Our data show that SSeCKS sup-
presses several critical proliferation- and angiogenesis-
associated genes while it induces differentiation and cell
cycle control functions, strongly suggesting that SSeCKS is
capable of reprogramming normal gene expression con-
trols downstream of activated Src.
Methods
Cells
S2-6 cells are NIH3T3 cells that encode a tetracycline (tet)-
regulated tTA transactivator (Tet-OFF), S24 cells are S2-6
cells encoding a tet-regulated rat SSeCKS cDNA, and S24/
ts72v-Src cells express temperature-sensitive v-Src whose
kinase activity is only active at the permissive temperature
(PT = 35°C), as described previously [6]. Cell cultures
were maintained in complete DMEM supplemented with
10% calf serum, penicillin/streptomycin/amphotericin B,
2 µg/ml puromycin (S24 and S24/ts72v-Src cells), 65 µg/
ml G418 (S24/ts72v-Src cells) and 0.7 mg/ml tet (Sigma).
Oligonucleotide array analysis
1 µg of total RNA, isolated from comparable cell groups
using TRIzol reagent (Invitrogen.), was reverse-tran-
scribed into Cy-3- and Cy-5-labeled probes used to
hybridize to Affymetrix A430 chips (Santa Clara, CA)
according to the manufacturer's protocol. Fluorescence
intensity for each chip was measured with an Affymetrix
428 Scanner. Data were derived from three independent
microarray analyses performed for each cell type, and
comparative analysis of resulting data was performed
using software suites including GeneSpring v5.0 (Silicon
Genetics), Data Mining Tool v3.0 (Affymetrix), GeneTraf-
fic Uno (Iobion Informatics), dChip v1.1 (Harvard Uni-
versity) and SAM v1.15 (Stanford University) [10]. The
mean hybridization signal for each sample was set as
1000 arbitrary units to normalize the signal values of all
of the genes on the chip (global normalization) between
different samples. The signal ratio of 2 or 0.5 was chosen
as the criterion for induction or repression, respectively.
In repeat experiments, most of the inter-experimental var-
iation in gene expression (of the genes listed in Tables 3,
4, 5) was less than 2-fold, and only a few genes varied
widely (e.g.- typically, 3.5- to 6-fold). However, these var-
iations did not alter the trends in gene regulation (i.e.- up-
or downregulation) by SSeCKS and/or v-Src.
RT-PCR
1 µg of total RNA was primed with oligo-dT16, reverse
transcribed into first strand cDNA and then amplified in
the linear range using the SuperScript® III RTS One-Step
RT-PCR Kit (Invitrogen), as described previously [1],
using the primer sets described in Table 1. The primer sets
for Gpr56, Maff, Socs3, Afp, Ngfb, Gadd45a, Marcks,
Hif1a, AFP, PDGFRB and HIF1A were purchased as
QuantiTect Primer Assays (Qiagen). Optimization of RT-
PCRs for semi-quantitative analysis was carried out after
normalization using the β-actin mRNA as an internal con-
trol. PCR products were electrophoresed in 1.6% agarose
gels, stained with ethidium bromide, and digitally imaged
using a Chemi-Genius2  BioImager (Syngene). Relative
intensities of PCR bands were quantified using GeneTools
image software analysis (Syngene).
Western blot
Blotting analysis was performed as described previously
[11] using the following primary antibodies at 1:1000
dilutions: PAb anti-SSeCKS [12], MAb anti- β-actin
(Sigma), anti-Src [poY418] (BioSource International),
MAb anti-v-Src (Ab-1; Oncogene Sciences). Secondary
PAbs were either horseradish peroxidase-conjugated anti-
rabbit or -mouse Ig (1:2,500; Chemicon) followed by
Lumi-Light chemiluminescence reagent (Roche).
Results and discussion
Conditional expression of SSeCKS and v-Src activation in 
mouse fibroblast cell lines
Our previous data indicated that SSeCKS overexpression
in untransformed fibroblasts induces cell flattening as
well as G1 phase growth arrest, the latter due to the sup-
pression of growth factor-induced cyclin D1 expression
[7]. The forced re-expression of SSeCKS could suppress v-
Src-induced oncogenic growth in vitro without grossly
affecting the ability of v-Src to phosphorylate cellular sub-
strates [6]. Therefore, in order to identify genes differen-
tially regulated by SSeCKS during G1 arrest or during
suppression of Src-induced oncogenesis, we used
NIH3T3-derived lines with tetracycline (Tet-OFF)-induci-
ble SSeCKS expression ("S24 cells") as well as S24 cells
expressing a temperature-sensitive v-Src allele ("S24/
ts72v-Src"). The ectopic expression of SSeCKS was
strongly induced (>25-fold) in the absence of tetracycline
(tet), yet in the presence of tet, ts72v-Src activation (35°C)
resulted in a >10-fold decrease in endogenous SSeCKS lev-
els (Fig. 1A), confirming our initial identification of
SSeCKS as a Src-suppressed gene [1]. Moreover, SSeCKS
overexpression did not affect Src autophosphorylation
activity, as monitored by phospho-Y416 levels (Fig. 1A).
The relationship between increased Src activity levels andBMC Cancer 2006, 6:105 http://www.biomedcentral.com/1471-2407/6/105
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decreased SSeCKS levels is also maintained when compar-
ing the metastatic human colon cancer cell line, HT29
(high Src activity, low Gravin), with the low metastatic
line, HCT116 (low Src activity, high Gravin) (Figure 1B).
We previously showed that growth of S24/ts72v-Src cells
in 0.04 µg/ml tet resulted in re-expression of ectopic
SSeCKS to the physiologic levels found in parental
NIH3T3 cells [6]. Therefore, as described in Table 2, we
compared differential gene expression for the following
conditions: i) SSeCKS overexpression in untransformed
cells (S24 grown in + vs. – tet at 37°C), ii) v-Src activation
without SSeCKS re-expression ([S24/ts72v-Src grown in
the presence of tet at 35°C vs. 39.5°C] minus [S24 grown
in the presence of tet at 35°C]), or iii) SSeCKS re-expres-
sion in the presence of activated v-Src (S24/ts72v-Src at
35°C grown in + vs. – tet).
Profile of SSeCKS-regulated gene expression
We identified 45 genes whose expression was altered 2-
fold or more by SSeCKS overexpression using at least three
independent Affymetrix microarray analyses, as described
in Materials and Methods, of RNA from S24 cells grown at
37°C in the presence or absence of tet. We then subtracted
gene expression effects induced by the tTA transactivator
alone in the absence of SSeCKS expression, that is, RNA
derived from S2-6 parental cells [13] grown in the absence
of tet. Given our prior results that SSeCKS overexpression
inhibits G1->S transition in untransformed fibroblasts
[7], it was not unexpected that ectopic SSeCKS could
induce tumor suppressor/cell cycle negative control genes
such as those encoding Rb, p19INK4 or Rassf5, while sup-
pressing cell cycle promoting genes, such as cyclins D, A,
B and F, Fos-like antigen 1, Afp [14] and the CDC20
homolog, or neoplasia-promoting genes such as Hmgb3
[15] or Cebpb [16] (Table 3). Similarly, SSeCKS induction
of Tgf-α and -β, and of Ngf-β, and the downregulation of
Mtap7, is consistent with the pseudo-differentiated, non-
polar phenotype displayed during SSeCKS-induced cell
flattening [13]. The loss of PDGFR-β expression, which we
have described elsewhere [17], likely relates to the ability
of SSeCKS to suppress angiogenesis in the brain [8] and in
tumor neovasculature. Of the signal transduction genes,
the upregulation of Ptplad1, Traf6 [18] and Lmo4 [19]
were consistent with the ability of SSeCKS to control cell
cycle progression. Stam2 upregulation or Peg3 downregu-
lation may facilitate SSeCKS-mediated anti-apoptosis
based on reported roles for Stam2 role T cell survival sig-
naling [20] and for Peg3 in neuronal death [21]. In con-
trast, SSeCKS unexpectedly upregulated several genes such
as Gpr56, Prkce and Btbd2 which have been reported to
be upregulated in human cancers [22,23] or involved in
inducing cell cycle progression [24], whereas it downreg-
ulated several genes such as Nasp, known to antagonize
cell cycle progression [25]. The role of other genes, such as
Gng2, in SSeCKS regulation remain unclear although they
are typically involved in specialized neuronal signaling
responses [26]; upregulation might suggest that SSeCKS
induces signaling pathways more associated with differen-
tiated, especially neuronal, cells. Interestingly, we previ-
ously published that SSeCKS overexpression in S24 cells
induces long axonal-like extensions which, when stained
for SSeCKS, exhibit periodic, pearl-like enrichments of
SSeCKS that are strikingly similar to SSeCKS-enriched
structures in developing hippocampal axons [27]. The
severe downregulation of Dusp9- which normally antago-
nizes insulin-mediated adipogenesis [28]- may reflect an
ability by SSeCKS to induce glucose uptake and/or metab-
olism, though this has not been studied. Mycbp is known
to inhibit PKA activation at various cell sites by preventing
recruitment of the PKA catalytic subunit to the scaffolding
proteins, S-AKAP84 and AKAP95 [29]. Thus, Mycbp
upregulation by SSeCKS- also a known AKAP [2]-may
SSeCKS/Gravin/AKAP12 downregulation by activated Src Figure 1
SSeCKS/Gravin/AKAP12 downregulation by activated Src. 
(A) Lysates from S24 and S24/ts72v-Src cells (grown at the 
PT) in the presence or absence of tet were immunoblotted 
for SSeCKS, activated Src (poY416) or actin. Note that 
SSeCKS overexpression (- tet) did not affect total ts72v-Src 
protein levels [6]. (B) A similar analysis as in panel A with 
lysates from HCT116 and HT29 human colon cancer cells 
with the addition of an immunoblot for total Src protein.
SSeCKS
Actin
SrcpoY416
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(hu-SSeCKS)
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Actin
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A
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reflect a higher level of temporal and/or spatial control of
PKA activity by SSeCKS.
Profile of v-Src-regulated gene expression
24 genes were identified whose expression varied 2-fold
or more by v-Src activation. Specifically, we compared
microarray data from RNAs derived from S24/ts72v-Src
cells grown in the presence of tet (i.e.- no ectopic SSeCKS)
at either 35°C (the PT for Src kinase activity) or 39.5°C
(the NPT) (Table 4, column A). To identify possible gene
changes induced by incubation at 39.5°C (and not by the
loss of Src activity), we compared microarray data derived
from S24/ts72v-Src cells versus S24 cells grown in the
presence of tet at 35°C (Table 4, column B). However,
gene expression changes that occur under the latter condi-
tions only (e.g.- Sh3bp5) might also reflect bona fide v-Src-
Table 1: Summary of primer sequences and positions
Target gene  Sequence of forward and reverse 
primers 
position
Mouse
Pdgfr-β 5'-AGCTACATGGCCCCTTATGA-3' 2749–2768
5'-GGATCCCAAAAGACCAGACA-3' 3069–3115
Tgfβ-1 5'-CGGGGCGACCTGGGCA 
CCATCCATGAC-3'
1597–1623
5'-
CTGCTCCACCTTGGGCTTGCGACCCAC-
3'
1975–2001
Cdc20 5'-GCTGGTTCTGGTGACATCCT-3' 757–776
5'-TGTTCCAACTGAGGGAGCTT-3' 939–958
Ptpn11 5'-AGTCCAAAGTGACCCACGTC-3' 623–643
5'-AGCGTCTCAAACTCTTCCCA-3' 874–893
Id2 5'-GGACATCAGCATCCTGTCCT-3' 383–402
5'-AACGGTATCACAGTCCAGGC-3' 659–678
Il1rl1 5'-CGCTCGACTTATCCTGTGGA-3' 299–318
5'-AGCTTGGCGGCTTTTTATGT-3' 490–509
Cdkn2d 5'AGCTTGGCGGCTTTTTATGT-3' 212–229
5'-CGGTCCCATTACTTGTCAC-3' 460–442
β- actin 5'-TTCTTTGCAGCTCCTTCGTTGCCG-3' 33–56
5'-TGGATGGCTACGTACATGGCTGGG-3' 467–490
Gpr56 Qiagen QuantiTect Assay, cat. #QT00178689
Maff Qiagen QuantiTect Assay, cat. #QT00133224
Ngfb Qiagen QuantiTect Assay, cat. #QT00093464
Socs3 Qiagen QuantiTect Assay, cat. #QT00100331
Gadd45a Qiagen QuantiTect Assay, cat. #QT00249655
Marcks Qiagen QuantiTect Assay, cat. #QT00252973
Hif1a Qiagen QuantiTect Assay, cat. #QT00182532
Afp Qiagen QuantiTect Assay, cat. #QT00174020
Human
CDC20A 5'-GGGTTCCTCTGCAGACATTC-3' 1034–1053
5'-TGTAATGGGGAGACCAGAGG-3' 1215–1234
PSCDBP 5'-TCAATGCAGCAATTGGAGTC-3' 741–761
5'-ATGTCAATGCACGTCAGCAT-3' 920–940
FOSL1 5'-CCAAGCATCAACACCATGAG-3' 302–321
5'-GGGCTGATCTGTTCACAAGG-3' 473–492
HMGA2 5'-CGAAAGGTGCTGGGCAGCTCCGG-3' 786–808
5'-CCATTTCCTAGGTCTGCCTCTTG-3' 1086–1110
HMGB3 5'-ACAACCGAGACAAACCCTTG-3' 1107–1126
5'-CCCCTTTGTCCACAGCTAAG-3' 1290–1310
β- ACTIN 5'-GCTCGTCGTCGACAACGGCTC-3' 93–113
5'-CAAACATGATCTGGGTCATCTTCTC-3' 445–421
AFP Qiagen QuantiTect Assay, cat. #QT00085183
PDGFRB Qiagen QuantiTect Assay, cat. #QT00082327
HIF1A Qiagen QuantiTect Assay, cat. #QT00083644BMC Cancer 2006, 6:105 http://www.biomedcentral.com/1471-2407/6/105
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induced changes that are negated at the NPT, and thus, we
included both column A and B data in our overall analy-
sis.
Six of the 24 genes (25%) were identified in Table 3 as
being inversely regulated by SSeCKS, i.e.- if they were
induced by SSeCKS, they were suppressed by v-Src, or vice-
a-versa. These include Peg3, Fosl1, Hmgb3, Gfra1, Il1rl1
and Afp. In contrast, Igfbp4 is dowregulated both by
SSeCKS overexpression and v-Src activation, lessening
confidence that this gene plays a significant role in onco-
genesis.
Rgs16, Id2 and Socs3 have paradoxical roles in that they
play both positive and negative functions in cancer. For
example, Rgs16- whose expression is induced by v-Src in
our system- is a GTPase activating protein for Gαi [30],
and Gαi is known to cooperate with Src in oncogenic
transformation [31]. However, Rgs16 activity is required
for retinoid-induced growth inhibition [32], suggesting
that it could antagonize cancer progression. Similarly,
Socs3- whose expression is also induced by v-Src, is
known to inhibit insulin-mediated proliferation signaling
[33] and to be downregulated in head and neck squamous
cell carcinomas [34], yet it is upregulated in breast cancer
[35]. Id2 plays positive roles in cancer, possibly by inhib-
iting parameters of differentiation [36], yet decreased Id2
levels correlate with increased invasive potential in
human breast cancer cases [37].
The increased levels of the transcription factors Maff,
Runx1 and Etv4, and the decreased levels of Centd3, Id4,
Spon2, and Cbr2 by v-Src seem to directly relate to cancer
progression. Specifically, Maff is overexpressed in some
forms of cancer [38] and Maf proteins play direct roles in
controlling v-Src-regulated gene expression [39]. Runx1
induces cell cycle progression [40] and increased Runx1
levels are found in chronic myelogenous leukemias [41].
Etv4 levels are increase in gastric cancers [42]. Centd2 is a
GAP for RhoA whose activity is blocked by phosphoryla-
tion by Src-family kinases [43]. Id4 is downregulated in
colon [44] and gastric cancers [45]. Spon2 and Cbr2 levels
are decreased significantly in lung cancers [46,47]. In con-
trast, v-Src induction of Prkg2 does not make apparent
sense given that higher Prkg2 levels correlate with
increased patient survival rates for lung cancer [48].
Finally, it is unclear how the differential regulation of
Sh3bp, Atoh6, Tcfec and Pscdbp would affect v-Src-
induced oncogenesis.
Profile of gene expression in cells expressing activated Src 
plus physiologic SSeCKS levels
46 genes were identified whose expression was altered
under conditions of activated v-Src and SSeCKS to physi-
ologic levels (Table 5). 16 of these genes (36%) were iden-
tified in screens described in Tables 3 or 4. Of these, 12
genes (Gpr56, Gng2, Ptplad1, Marcks, Cdkn2d, Cdc2a,
Hmgb3, Ngfb, Gfra1, Il1rl1, Pdgfrb and Afp) exhibited the
same expression control (i.e.- up-or downregulation) as
detected after SSeCKS overexpression alone (Table 3).
This strongly suggests that these genes are markers for
SSeCKS-mediated growth arrest and/or tumor suppres-
sion. The remaining 4 pre-identified genes (Socs3, Maff,
Id2 and Atoh6) are regulated in the same manner as in v-
Src-transformed cells (Table 4) and thus, it is likely that
these genes remain controlled by v-Src yet are not suffi-
cient for the oncogenic phenotype.
SSeCKS reverses the expression of several genes that might
either antagonize v-Src-induced oncogenesis or function
as markers for non-transformed cells. Specifically, SSeCKS
induces the expression of Gadd45a- a gene known to
inhibit progression at either S or G2/M phases [49] or to
induce density-dependent G1 phase arrest [50], Cdkn2d,
Rbbp7- which inhibits mitogen- and oncogene-induced c-
Fos activation [51], and Dub1- whose overexpression
induces G1 arrest [52]. In the same context, SSeCKS sup-
presses the expression of Map2kb- whose activity is
increased in Ras-mediated invasiveness and metastatic
potential [53], Rgs2- whose increased expression in man-
tle cell lymphomas correlates with increased metastatic
potential [54], Tcfap4- a regulator of caspase-9 mediated
apoptosis [55], Cdc2a, Hif1a- a mediator of tumor angio-
genesis induced by v-Src [56,57] and activated c-Src
[58,59], Ddit4- an Hif1a-inducible gene [60], and Pdgfrb.
Interestingly, SSeCKS re-expression may facilitate
increased immune surveillance of tumor cells by the
induction of Hsp4a, a tumor antigen carrier that increases
the immunogenicity of colon cancer cells in a murine
model [61]. Although the decrease in Caspase-7 (Casp7)
expression correlates with the decreased apoptotic index
of v-Src cells re-expressing SSeCKS [6], it is unclear how
Table 2: The cell groups/conditions used to compare gene expression
Cells/Growth condition Comparison
NIH3T3/S24 cells, + vs. – tet, 37°C SSeCKS overexpression
([S24/ts72v-Src cells, 35°C vs. 39.5°C] minus 
S24 cells, 35°C), + tet (1 µg/ml)
v-Src activation
S24/ts72v-Src cells, 35°C, 1.0 vs.0.04 µg/ml tet SSeCKS re-expression plus v-Src activationBMC Cancer 2006, 6:105 http://www.biomedcentral.com/1471-2407/6/105
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the concomitant increase in Stk4- a pro-apoptotic serine/
threonine kinase [62], affects cell survival after SSeCKS re-
expression.
A set of genes seems to remain regulated by v-Src during
SSeCKS re-expression, suggesting that their expression lev-
els are not sufficient to induce or maintain oncogenic
transformation in the presence of physiologic levels of
SSeCKS. These include Ptpn11- which can activate Src-
family kinases [63] and which is required for v-Src-
induced morphological transformation [64], Pip5k1b-
whose product is activated by Rho-family GTPases in can-
cer cells [65], Srpk2- a gene upregulated after retinoid-
induced differentiation of HL60 leukemia cells [66],
Dusp10- a negative regulator of MAP kinases and antago-
nist of prostate cancer cell proliferation [67], Marcks,
Timp3- a gene downregulated in squamous cell carcino-
mas and prostate adenocarcinomas [68,69], Gdf5- a
growth arrest inducer in mouse B cells [70], and Gas1- a
gene downregulated in EGF-induced hepatocellular carci-
noma [71] and in Ras-transformed cells [72]. The involve-
ment of S100a8 is unclear because although its expression
is induced in prostate cancer [73], its expression is down-
regulated in the metastatic breast cancer cell line, MDA-
MB-231, compared to the non-metastatic MCF-7 [74].
In order to verify the gene expression changes identified in
the microarray studies, several genes were assayed by
semi-quantitative RT-PCR using primer sets shown in
Table 1. Thus, RNAs derived from S24 or S24/ts72v-Src
cells grown at the PT in the presence or absence of tet were
amplified by RT-PCR as described in Materials and Meth-
ods and then the electrophoresed products were quanti-
fied by digital densitometry. Fig. 2A and Table 6 show a
strong concordance between the regulation of Cdc2a,
Il1rl1, Cdkn2d, Pdgfrb, Ptpn11, Tgfb1, Id2, Gpr56, Maff,
Socs, Afp, Ngfb, Gadd45a, Marcks and Hif1a by either
SSeCKS alone or SSeCKS re-expression in the presence of
v-Src as gauged by both the microarray and RT-PCR
assays. This strengthens the notion that the genes identi-
fied by our microarray comparisons reflect bona fide exam-
ples of differential expression due to SSeCKS
overexpression or SSeCKS re-expression in the presence of
active v-Src. Finally, we performed semi-quantitative RT-
PCR on several genes shown to be induced by active v-Src
(Table 3) using RNAs from HT29 and HCT116, represent-
ing cells with high and low levels of c-Src activity, respec-
tively (Fig. 1B). Fig. 2B shows significantly higher levels of
HMGA2, FOSL1, CDC20A, PSCDBP, AFP, PDGFRB and
HIF1A expression in HT29 cells, which correlates with the
v-Src-induced levels found for the mouse orthologues in
Table 4 (for both cell comparisons A and B). In contrast,
HMGB3 transcript levels were similar in HT29 and
HCT116 cells, correlating with the finding that its mouse
orthologue was likely not induced by v-Src (Table 4, col-
umn B). Taken together, these data strongly suggest that
activated Src and SSeCKS/Gravin control similar sets of
Verification of differential gene expression using semi-quanti- tative RT-PCR Figure 2
Verification of differential gene expression using semi-quanti-
tative RT-PCR. Equal amounts of total RNA isolated from 
S24 or S24/ts72v-Src cells (grown at the PT) in the presence 
or absence of tet (Panel A) or from HCT116 or HT29 (Panel 
B) were subjected to RT-PCR analysis as described in Materi-
als and Methods using primer sets described in Table 1. 
These results are typical of at least two independent experi-
ments.
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genes in both human and mouse fibroblasts and epithe-
lial cells.
Conclusion
We have identified sets of genes whose expression is con-
trolled either by SSeCKS or v-Src alone, or only after re-
expression of SSeCKS in the presence of activated v-Src.
Our data suggest that some or all of the SSeCKS-regulated
genes may either directly antagonize v-Src-induced onco-
genesis or may serve as markers for non-oncogenic cells.
Moreover, our analysis has identified a set of genes previ-
ously thought to contribute to the oncogenic phenotype
Table 3: Genes Regulated by SSeCKS in NIH3T3 fibroblastsa A value ≥ 2 represents induction; a value ≤ 0.5 represents repression
Gene Symbol Modulation
Signal transduction
G protein-coupled receptor 56 Gpr56 126.24*
BTB (POZ) domain containing 2 Btbd2 10.85
Guanine nucleotide binding protein (G protein), gamma 2 subunit Gng2 9.58*
Ras association (RalGDS/AF-6) domain family 5 Rassf5 8.75
Calcium binding protein 2 Cabp2 8.11
Butyrate-induced transcript 1 Ptplad1 4.08*
Signal-transducing adaptor protein-2 Stam2 3.20
Protein kinase C, epsilon Prkce 2.36
Interferon-stimulated protein G1p2 2.30
Tnf receptor-associated factor 6 Traf6 2.23
RAB33B, member of RAS oncogene family Rab33b 2.17
Insulin-like growth factor 2, binding protein 3 Igf2bp3 0.49
Myristoylated alanine rich protein kinase C substrate Marcks 0.48*
Insulin-like growth factor binding protein 4 Igfbp4 0.47
N-myc downstream regulated 1 Ndrg1 0.41
Paternally expressed 3 Peg3 0.27
Dual specificity phosphatase 9 Dusp9 0.15
Cell cycle and transcriptional regulator
Retinoblastoma 1 Rb1 3.48
c-myc binding protein Mycbp 3.41
Histone 2, H2aa1 Hist2h2aa1 3.07
Histone 3, H2a Hist3h2a 2.99
Zinc fingers and homeoboxes protein 1 Zhx1 2.79
Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) Cdkn2d 2.73*
CCAAT/enhancer binding protein (C/EBP), beta Cebpb 0.50
Cyclin F Ccnf 0.48
Cyclin A2 Ccna2 0.47
High mobility group box 1 Hmgb1 0.46
cell division cycle 20 homolog (S. cerevisiae) Cdc20a 0.46*
Cyclin B1 Ccnb1 0.44
LIM domain only 4 Lmo4 0.44
Fos-like antigen 1 Fosl1 0.41
Cyclin D1 Ccnd1 0.37
High mobility group box 3 Hmgb3 0.24*
Nuclear autoantigenic sperm protein (histone-binding) Nasp 0.06
Cytoskeleton
Synaptonemal complex protein 3 Sycp3 8.34
Microtubule-associated protein 7 Mtap7 0.18
Growth factor and receptor
Transforming growth factor, beta 1 Tgfb1 2.33
Nerve growth factor, beta Ngfb 2.28*
Transforming growth factor alpha Tgfa 2.27
Platelet derived growth factor receptor, beta polypeptide Pdgfrb 0.30*
Interleukin 1 receptor-like 1 Il1rl1 0.29*
Glial cell line derived neurotrophic factor family receptor alpha 1 Gfra1 0.15*
Others
Alpha fetoprotein Afp 0.32*
aS24 MEF, 37°C, Tet (-) vs (+)
* Similar effects after SSeCKS re-expression in v-Src transformed cells (Table 5).BMC Cancer 2006, 6:105 http://www.biomedcentral.com/1471-2407/6/105
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yet which are insufficient to induce oncogenesis in the
presence of physiologic levels of SSeCKS. In sum, our data
indicate that SSeCKS may antagonize Src-induced onco-
genesis through the normalization of functions control-
ling mitogenic signaling pathways, cell cycle progression,
transcriptional regulation and apoptosis.
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Table 4: Genes regulated by ts72v-Src activation A value ≥ 2 represents induction; a value ≤ 0.5 represents repression
Modulation
Gene Symbol AB
Signal Transduction
regulator of G-protein signaling 16 Rgs16 10.13 12.70
suppressor of cytokine signaling 3 Socs3 3.89 3.00
paternally expressed 3 Peg3 3.22* 3.50*
protein kinase, cGMP-dependent, type II Prkg2 2.53 2.30
insulin-like growth factor binding protein 4 Igfbp4 0.15** 0.42**
SH3-domain binding protein 5 (BTK-associated) Sh3bp5 NC 0.29
ARF-GAP, RHO-GAP, ankyrin repeat and plekstrin homology domains-containing protein 3 Centd3 0.08 0.05
Cell cycle and transcriptional regulator
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F Maff 17.03 3.00
high mobility group AT-hook 2 Hmga2 6.96 5.00
runt related transcription factor 1, RUN X1/AML-1 Runx1 6.77 5.50
ets variant gene 4 (E1A enhancer binding protein, E1AF) Etv4 6.68 8.30
fos-like antigen 1 Fosl1 4.47* 2.80*
high mobility group box 3 Hmgb3 3.73* 3.30*
transcription factor EC Tcfec NC 63.00
inhibitor of DNA binding 4 Id4 0.22 NC
inhibitor of DNA binding 2 Id2 NC 0.43
basic helix-loop-helix transcription factor 6 Atoh8 0.15 0.29
Growth factor and receptor
glial cell line derived neurotrophic factor family receptor alpha 1 Gfra1 4.17* 7.00*
interleukin 1 receptor-like 1 Il1rl1 4.20* 3.50*
Others
pleckstrin homology, Sec7 and coiled-coil domains, binding protein Pscdbp 4.08 3.30
alpha fetoprotein Afp 3.89* 3.80*
spondin 2, extracellular matrix protein Spon2 0.13 0.23
carbonyl reductase 2 Cbr2 0.11 0.07
A, S24/ts72v-Src cells, 35°C vs 39.5°C, + tet.
B, S24/ts72v-Src cells, 35°C vs S24 MEF 35°C, + tet.
*, opposite effect when compared to SSeCKS overexpression alone (Table 3).
**, similar effects when compared to SSeCKS overexpression alone (Table 3).
NC, no change.BMC Cancer 2006, 6:105 http://www.biomedcentral.com/1471-2407/6/105
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Table 5: Genes regulated by SSeCKS in v-Src transformed cellsa A value ≥ 2 represents induction; a value ≤ 0.5 represents repression
Gene  Symbol Modulation
Signal transduction
Cytokine inducible kinase Plk3 52.35
G protein-coupled receptor 56 Gpr56 49.00*
Guanine nucleotide binding protein (G protein), gamma 2 subunit Gng2 7.16*
Protein tyrosine phosphatase, non-receptor type 11 Ptpn11 5.86
Serine/threonine kinase 4 Stk4 3.97
RAB20, member RAS oncogene family Rab20 3.92
Phosphatidylinositol-4-phosphate 5-kinase, type 1 beta Pip5k1b 3.50
Growth arrest and DNA-damage-inducible 45 alpha Gadd45a 3.43
Butyrate-induced transcript 1 Ptplad1 3.29*
Suppressor of cytokine signaling 3 Socs3 2.07***
Serine/arginine-rich protein specific kinase 2 Srpk2 0.45
Mitogen activated protein kinase kinase 6 Map2k6 0.44
Regulator of G-protein signaling 2 Rgs2 0.38
Ras and Rab interactor 2 Rin2 0.33
Dual specificity phosphatase 10 Dusp10 0.17
Myristoylated alanine rich protein kinase C substrate Marcks 0.12*
Cell cycle and transcriptional regulator
Histone 1, H2bp Hist1h2bp 3.61
Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) Cdkn2d 2.46*
Retinoblastoma binding protein 7 Rbbp7 2.39
Histone 2, H3c2 Hist2h3c2 2.28
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F Maff 2.28***
Inhibitor of DNA binding 2 Id2 0.44***
Transcription factor AP-4 (activating enhancer-binding protein 4) Tcfap4 0.26
Cell division cycle 20 homolog (S. cerevisiae) Cdc2a 0.25*
Basic helix-loop-helix transcription factor 6 Atoh6 0.24***
High mobility group box 3 Hmgb3 0.24*/**
Hypoxia inducible factor 1, alpha subunit Hif1a 0.22
Kruppel-like factor 7 (ubiquitous) Klf7 0.10
Growth factor and receptor
Chemokine (C-C motif) ligand 2 Ccl2 4.26
Nerve growth factor, beta Ngfb 2.38*
Glial cell line derived neurotrophic factor family receptor alpha 1 Gfra1 0.33*/**
Interleukin 1 receptor-like 1 Il1rl1 0.23*/**
Platelet derived growth factor receptor, beta polypeptide Pdgfrb 0.18*
Transforming growth factor, beta 2 Tgfb2 0.14
Others
S100 calcium binding protein A8 (calgranulin A) S100a8 16.22
Fatty acid desaturase 3 Fads3 8.00
Heat shock protein 4 Hspa4 4.29
Deubiquitinating enzyme 1 Dub1 3.23
alpha fetoprotein Afp 0.50*/**
Tissue inhibitor of metalloproteinase 3 Timp3 0.33
HIF-1 responsive RTP801 Ddit4 0.26
5-azacytidine induced gene 1 Azi1 0.24
Growth differentiation factor 5 Gdf5 0.18
Growth arrest specific 1 Gas1 0.18
Caspase 7 Casp7 0.18
retinitis pigmentosa 1 homolog (human) Rp1h 0.12
protocadherin 18 Pcdh18 0.07
a, S24/ts72v-Src MEF, 35 °C, + vs – tet.
*, similar effects when compared to SSeCKS overexpression alone (Table 3).
**, opposite effects when compared to v-Src activation (Table 4).
***, similar effects when compared to v-Src activation (Table 4).BMC Cancer 2006, 6:105 http://www.biomedcentral.com/1471-2407/6/105
Page 10 of 12
(page number not for citation purposes)
References
1. Lin X, Nelson PJ, Frankfort B, Tombler E, Johnson R, Gelman IH: Iso-
lation and characterization of a novel mitogenic regulatory
gene, 322, which is transcriptionally suppressed in cells
transformed by src and ras.  Mol Cell Biol 1995, 15:2754-2762.
2. Nauert J, Klauck T, Langeberg LK, Scott JD: Gravin, an autoanti-
gen recognized by serum from myasthenia gravis patients, is
a kinase scaffolding protein.  Current Biology 1997, 7:52-62.
3. Gordon T, Grove B, Loftus JC, O'Toole T, McMillan R, Lindstrom J,
Ginsberg MH: Molecular cloning and prelimnary characteriz-
tion of a novel cytoplasmic antigen recognized by myasthe-
nia gravis sera.  J Clin Invest 1992, 90:992-999.
4. Xia W, Unger P, Miller L, Nelson J, Gelman IH: The src-suppressed
C kinase substrate, SSeCKS, is a potential metastasis inhibi-
tor in prostate cancer.  Cancer Res 2001, 15:5644-5651.
5. Gelman IH: The role of the SSeCKS/Gravin/AKAP12 scaffold-
ing proteins in the spaciotemporal control of signaling path-
ways in oncogenesis and development.  Front Biosci 2002,
7:1797.
6. Lin X, Gelman IH: Re-expression of the major protein kinase C
substrate, SSeCKS, suppresses v-src- induced morphological
transformation and tumorigenesis.  Cancer Res 1997,
57:2304-2312.
7. Lin X, Nelson P, Gelman IH: Regulation of G->S Progression by
the SSeCKS Tumor Suppressor: Control of Cyclin D Expres-
sion and Cellular Compartmentalization.  Mol Cell Biol 2000,
20:7259-7272.
8. Lee SW, Kim WJ, Choi YK, Song HS, Son MJ, Gelman IH, Kim YJ, Kim
KW: SSeCKS regulates angiogenesis and tight junction for-
mation in blood-brain barrier.  Nat Med 2003, 9:900-906.
9. Su B, Zheng Q, Vaughan MM, Bu Y, Gelman IH: SSeCKS metasta-
sis-suppressing activity correlates with angiogenesis inhibi-
tion.  Cancer Res 2006 in press.
10. Tusher VG, Tibshirani R, Chu G: Significance analysis of micro-
arrays applied to the ionizing radiation response.  Proc Natl
Acad Sci USA 2001, 98:5116-5121.
11. Moissoglu K, Gelman IH: v-Src Rescues Actin-Based Cytoskele-
tal Architecture and Cell Motility, and Induces Enhanced
Anchorage-Independence During Oncogenic Transforma-
tion of FAK-Null Fibroblasts.  J Biol Chem 2003,
278:47946-47959.
12. Lin X, Tombler E, Nelson PJ, Ross M, Gelman IH: A novel src- and
ras-suppressed protein kinase C substrate associated with
cytoskeletal architecture.  J Biol Chem 1996, 271:430-28.
13. Gelman IH, Lee K, Tombler E, Gordon R, Lin X: Control of
cytoskeletal architecture by the src-suppressed C kinase sub-
strate, SSeCKS.  Cell Motil Cytoskeleton 1998, 41:1-17.
14. Li MS, Li PF, Yang FY, He SP, Du GG, Li G: The intracellular mech-
anism of alpha-fetoprotein promoting the proliferation of
NIH 3T3 cells.  Cell Res 2002, 12:151-156.
15. Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto
AJ, Parlow AF, Visone R, Pierantoni GM, Outwater E, Santoro M,
Croce CM, Fusco A: Overexpression of the HMGA2 gene in
transgenic mice leads to the onset of pituitary adenomas.
Oncogene 2002, 21:3190-3198.
16. Zhu S, Yoon K, Sterneck E, Johnson PF, Smart RC: CCAAT/
enhancer binding protein-beta is a mediator of keratinocyte
survival and skin tumorigenesis involving oncogenic Ras sig-
naling.  Proc Natl Acad Sci USA 2002, 99:207-212.
17. Su B, Zheng Q, Vaughan MM, Bu Y, Gelman IH: SSeCKSmetasta-
sis-suppressing activity in MatLyLu prostate cancer cellscor-
relates with VEGF inhibition.  Cancer Res 2006 in press.
18. Bharti AC, Takada Y, Shishodia S, Aggarwal BB: Evidence that
receptor activator of nuclear factor (NF)-kappaB ligand can
suppress cell proliferation and induce apoptosis through
activation of a NF-kappaB-independent and TRAF6-depend-
ent mechanism.  J Biol Chem 2004, 279:6065-6076.
19. Sum EY, Shackleton M, Hahm K, Thomas RM, O'Reilly LA, Wagner
KU, Lindeman GJ, Visvader JE: Loss of the LIM domain protein
Lmo4 in the mammary gland during pregnancy impedes lob-
uloalveolar development.  Oncogene 2005, 24:4820-4828.
20. Yamada M, Ishii N, Asao H, Murata K, Kanazawa C, Sasaki H, Suga-
mura K: Signal-transducing adaptor molecules STAM1 and
STAM2 are required for T-cell development and survival.
Mol Cell Biol 2002, 22:8648-8658.
21. Johnson MD, Wu X, Aithmitti N, Morrison RS: Peg3/Pw1 is a
mediator between p53 and Bax in DNA damage-induced
neuronal death.  J Biol Chem 2002, 277:23000-23007.
22. Shashidhar S, Lorente G, Nagavarapu U, Nelson A, Kuo J, Cummins J,
Nikolich K, Urfer R, Foehr ED: GPR56 is a GPCR that is overex-
pressed in gliomas and functions in tumor cell adhesion.
Oncogene 2005, 24:1673-1682.
23. Yamada A, Kawano K, Koga M, Takamori S, Nakagawa M, Itoh K:
Gene and peptide analyses of newly defined lung cancer anti-
Table 6: Comparison of microarray and RT-PCR data
Fold change (array) Fold change (RT-PCR)a
Gene SSeCKS Inductionb SSeCKS induction plus v-
Src activationc
SSeCKS induction SSeCKS induction plus v-
Src activation
Cdc2a 0.46 0.25 0.27 0.25
Il1rl1 0.29 0.23 0.31 0.36
Cdkn2d 2.73 2.46 3.10 3.50
Pdgfrb 0.30 0.18 0.34 0.30
Ptpn11 NC* 5.86 NC 3.04
Tgfb1 2.33 NC 2.50 NC
Id2 NC 0.44 NC 0.33
Gpr56 126.24 49.00 45.0 28.0
Maff NC 2.28 NC 3.5
Socs3 NC 2.07 NC 2.4
Afp 0.32 0.50 0.4 0.2
Ngfb 2.28 2.38 8.0 2.5
Gadd45a NC 3.43 4.0 3.0
Marcks 0.48 0.12 NC 0.2
Hif1a NC 0.22 NC 0.3
a, based on two independent experiments. SE < 0.005.
b, from Table 3.
c, from Table 5.
NC, no change.BMC Cancer 2006, 6:105 http://www.biomedcentral.com/1471-2407/6/105
Page 11 of 12
(page number not for citation purposes)
gens recognized by HLA-A2402-restricted tumor-specific
cytotoxic T lymphocytes.  Cancer Res 2003, 63:2829-2835.
24. Soh JW, Weinstein IB: Roles of specific isoforms of protein
kinase C in the transcriptional control of cyclin D1 and
related genes.  J Biol Chem 2003, 278:34709-34716.
25. Alekseev OM, Bencic DC, Richardson RT, Widgren EE, O'Rand MG:
Overexpression of the Linker histone-binding protein
tNASP affects progression through the cell cycle.  J Biol Chem
2003, 278:8846-8852.
26. Varga EV, Hosohata K, Borys D, Navratilova E, Nylen A, Vanderah
TW, Porreca F, Roeske WR, Yamamura HI: Antinociception
depends on the presence of G protein gamma2-subunits in
brain.  Eur J Pharmacol 2005, 508:93-98.
27. Gelman IH, Tombler E, Vargas J Jr: A role for SSeCKS, a major
protein kinase C substrate with tumor suppressor activity, in
cytoskeletal architecture, formation of migratory processes,
and cell migration during embryogenesis.  Histochemical Journal
2000, 32:13-26.
28. Xu H, Dembski M, Yang Q, Yang D, Moriarty A, Tayber O, Chen H,
Kapeller R, Tartaglia LA: Dual specificity mitogen-activated pro-
tein (MAP) kinase phosphatase-4 plays a potential role in
insulin resistance.  J Biol Chem 2003, 278:30187-30192.
29. Furusawa M, Taira T, Iguchi-Ariga SM, Ariga H: AMY-1 interacts
with S-AKAP84 and AKAP95 in the cytoplasm and the
nucleus, respectively, and inhibits cAMP-dependent protein
kinase activity by preventing binding of its catalytic subunit
to A-kinase-anchoring protein (AKAP) complex.  J Biol Chem
2002, 277:50885-50892.
30. Nagata Y, Oda M, Nakata H, Shozaki Y, Kozasa T, Todokoro K: A
novel regulator of G-protein signaling bearing GAP activity
for Galphai and Galphaq in megakaryocytes.  Blood 2001,
97:3051-3060.
31. Ram PT, Iyengar R: G protein coupled receptor signaling
through the Src and Stat3 pathway: role in proliferation and
transformation.  Oncogene 2001, 20:1601-1606.
32. Liu T, Bohlken A, Kuljaca S, Lee M, Nguyen T, Smith S, Cheung B,
Norris MD, Haber M, Holloway AJ, Bowtell DD, Marshall GM: The
retinoid anticancer signal: mechanisms of target gene regu-
lation.  Br J Cancer 2005, 93:310-318.
33. Ueki K, Kondo T, Kahn CR: Suppressor of cytokine signaling 1
(SOCS-1) and SOCS-3 cause insulin resistance through inhi-
bition of tyrosine phosphorylation of insulin receptor sub-
strate proteins by discrete mechanisms.  Mol Cell Biol 2004,
24:5434-5446.
34. Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F,
Markwarth A, Dietz A, Wittekind C, Tannapfel A: SOCS-3 is fre-
quently methylated in head and neck squamous cell carci-
noma and its precursor lesions and causes growth inhibition.
Oncogene 2005, 24:6699-6708.
35. Raccurt M, Tam SP, Lau P, Mertani HC, Lambert A, Garcia-Caballero
T, Li H, Brown RJ, McGuckin MA, Morel G, Waters MJ: Suppressor
of cytokine signalling gene expression is elevated in breast
carcinoma.  Br J Cancer 2003, 89:524-532.
36. De Candia P, Benera R, Solit DB: A role for Id proteins in mam-
mary gland physiology and tumorigenesis.  Adv Cancer Res 2004,
92:81-94.
37. Stighall M, Manetopoulos C, Axelson H, Landberg G: High ID2 pro-
tein expression correlates with a favourable prognosis in
patients with primary breast cancer and reduces cellular
invasiveness of breast cancer cells.  Int J Cancer 2005,
115:403-411.
38. Kienast J, Berdel WE: c-maf in multiple myeloma: an oncogene
enhancing tumor-stroma interactions.  Cancer Cell 2004,
5:109-110.
39. Provot S, Pouponnot C, Lecoq O, Calothy G, Felder-Schmittbuhl MP:
Characterization of a novel quiescence responsive element
downregulated by v-Src in the promoter of the neuroretina
specific QR1 gene.  Oncogene 2000, 19:4736-4745.
40. Bernardin-Fried F, Kummalue T, Leijen S, Collector MI, Ravid K,
Friedman AD: AML1/RUNX1 increases during G1 to S cell
cycle progression independent of cytokine-dependent phos-
phorylation and induces cyclin D3 gene expression.  J Biol
Chem 2004, 279:15678-15687.
41. Yanagida M, Osato M, Yamashita N, Liqun H, Jacob B, Wu F, Cao X,
Nakamura T, Yokomizo T, Takahashi S, Yamamoto M, Shigesada K,
Ito Y: Increased dosage of Runx1/AML1 acts as a positive
modulator of myeloid leukemogenesis in BXH2 mice.  Onco-
gene 2005, 24:4477-4485.
42. Yamamoto H, Horiuchi S, Adachi Y, Taniguchi H, Nosho K, Min Y,
Imai K: Expression of ets-related transcriptional factor E1AF
is associated with tumor progression and over-expression of
matrilysin in human gastric cancer.  Carcinogenesis 2004,
25:325-332.
43. ST I, Nie Z, Stewart A, Najdovska M, Hall NE, He H, Randazzo PA,
Lock P: ARAP3 is transiently tyrosine phosphorylated in cells
attaching to fibronectin and inhibits cell spreading in a
RhoGAP-dependent manner.  J Cell Sci 2004, 117:6071-6084.
44. Umetani N, Takeuchi H, Fujimoto A, Shinozaki M, Bilchik AJ, Hoon
DS: Epigenetic inactivation of ID4 in colorectal carcinomas
correlates with poor differentiation and unfavorable progno-
sis.  Clin Cancer Res 2004, 10:7475-7483.
45. Chan AS, Tsui WY, Chen X, Chu KM, Chan TL, Chan AS, Li R, So S,
Yuen ST, Leung SY: Downregulation of ID4 by promoter hyper-
methylation in gastric adenocarcinoma.  Oncogene 2003,
22:6946-6953.
46. Takenaka K, Ogawa E, Oyanagi H, Wada H, Tanaka F: Carbonyl
reductase expression and its clinical significance in non-
small-cell lung cancer.  Cancer Epidemiol Biomarkers Prev 2005,
14:1972-1975.
47. Manda R, Kohno T, Matsuno Y, Takenoshita S, Kuwano H, Yokota J:
Identification of genes (SPON2 and C20orf2) differentially
expressed between cancerous and noncancerous lung cells
by mRNA differential display.  Genomics 1999, 61:5-14.
48. Ikehara M, Oshita F, Sekiyama A, Hamanaka N, Saito H, Yamada K,
Noda K, Kameda Y, Miyagi Y: Genome-wide cDNA microarray
screening to correlate gene expression profile with survival
in patients with advanced lung cancer.  Oncol Rep 2004,
11:1041-1044.
49. Vairapandi M, Balliet AG, Hoffman B, Liebermann DA: GADD45b
and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role
in S and G2/M cell cycle checkpoints induced by genotoxic
stress.  J Cell Physiol 2002, 192:327-338.
50. Zhang X, Ma L, Enkemann SA, Pledger WJ: Role of Gadd45alpha in
the density-dependent G1 arrest induced by p27(Kip1).  Onco-
gene 2003, 22:4166-4174.
51. Yang J, Kiefer S, Rauchman M: Characterization of the gene
encoding mouse retinoblastoma binding protein-7, a compo-
nent of chromatin-remodeling complexes.  Genomics 2002,
80:407-415.
52. Zhu Y, Carroll M, Papa FR, Hochstrasser M, D'Andrea AD: DUB-1,
a deubiquitinating enzyme with growth-suppressing activity.
Proc Natl Acad Sci USA 1996, 93:3275-3279.
53. Shin I, Kim S, Song H, Kim HR, Moon A: H-Ras-specific activation
of Rac-MKK3/6-p38 pathway: its critical role in invasion and
migration of breast epithelial cells.  J Biol Chem 2005,
280:14675-14683.
54. Zhu Y, Hollmen J, Raty R, Aalto Y, Nagy B, Elonen E, Kere J, Mannila
H, Franssila K, Knuutila S: Investigatory and analytical
approaches to differential gene expression profiling in man-
tle cell lymphoma.  Br J Haematol 2002, 119:905-915.
55. Tsujimoto K, Ono T, Sato M, Nishida T, Oguma T, Tadakuma T: Reg-
ulation of the expression of caspase-9 by the transcription
factor activator protein-4 in glucocorticoid-induced apopto-
sis.  J Biol Chem 2005, 280:27638-27644.
56. Jiang BH, Agani F, Passaniti A, Semenza GL: V-SRC induces expres-
sion of hypoxia-inducible factor 1 (HIF-1) and transcription
of genes encoding vascular endothelial growth factor and
enolase 1: involvement of HIF-1 in tumor progression.  Cancer
Res 1997, 57:5328-5335.
57. Gleadle JM, Ratcliffe PJ: Induction of hypoxia-inducible factor-1,
erythropoietin, vascular endothelial growth factor, and glu-
cose transporter-1 by hypoxia: evidence against a regulatory
role for Src kinase.  Blood 1997, 89:503-509.
58. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gal-
lick GE: HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are
components of a transcriptional complex that regulates Src-
dependent hypoxia-induced expression of VEGF in pancre-
atic and prostate carcinomas.  Oncogene 2005, 24:3110-3120.
59. Karni R, Dor Y, Keshet E, Meyuhas O, Levitzki A: Activated pp60c-
Src leads to elevated hypoxia-inducible factor (HIF)-1alpha
expression under normoxia.  J Biol Chem 2002, 277:42919-42925.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2006, 6:105 http://www.biomedcentral.com/1471-2407/6/105
Page 12 of 12
(page number not for citation purposes)
60. Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S, Moshel
Y, Elbaz S, Budanov A, Chajut A, Kalinski H, Kamer I, Rozen A, Mor
O, Keshet E, Leshkowitz D, Einat P, Skaliter R, Feinstein E: Identifi-
cation of a novel hypoxia-inducible factor 1-responsive gene,
RTP801, involved in apoptosis.  Mol Cell Biol 2002, 22:2283-2293.
61. Wang XY, Li Y, Manjili MH, Repasky EA, Pardoll DM, Subjeck JR:
Hsp110 over-expression increases the immunogenicity of
the murine CT26 colon tumor.  Cancer Immunol Immunother
2002, 51:311-319.
62. Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang
XF, Seed B, Avruch J: Identification of a novel Ras-regulated
proapoptotic pathway.  Curr Biol 2002, 12:253-265.
63. Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, Luo
J, Thompson JA, Schraven BL, Philips MR, Neel BG: Shp2 regulates
SRC family kinase activity and Ras/Erk activation by control-
ling Csk recruitment.  Mol Cell 2004, 13:341-355.
64. Hakak Y, Hsu YS, Martin GS: Shp-2 mediates v-Src-induced mor-
phological changes and activation of the anti-apoptotic pro-
tein kinase Akt.  Oncogene 2000, 19:3164-3171.
65. Weernink PA, Meletiadis K, Hommeltenberg S, Hinz M, Ishihara H,
Schmidt M, Jakobs KH: Activation of type I phosphatidylinositol
4-phosphate 5-kinase isoforms by the Rho GTPases, RhoA,
Rac1, and Cdc42.  J Biol Chem 2004, 279:7840-7849.
66. Yen A, Lin DM, Lamkin TJ, Varvayanis S: retinoic acid, bromode-
oxyuridine, and the Delta 205 mutant polyoma virus middle
T antigen regulate expression levels of a common ensemble
of proteins associated with early stages of inducing HL-60
leukemic cell differentiation.  In Vitro Cell Dev Biol Anim 2004,
40:216-241.
67. He HY, Fang WG, Zheng J, You JF, Heng WJ, Li Y: [Mechanism of
the mitogen-activated protein kinase phosphatase-5 regulat-
ing the growth and invasion of a human prostate cancer cell
line].  Zhonghua Yi Xue Za Zhi 2003, 83:1812-1817.
68. Kettunen E, Anttila S, Seppanen JK, Karjalainen A, Edgren H, Lind-
strom I, Salovaara R, Nissen AM, Salo J, Mattson K, Hollmen J, Knuu-
tila S, Wikman H: Differentially expressed genes innonsmall
cell lung cancer: expression profiling of cancer-related genes
in squamous cell lung cancer.  Cancer Genet Cytogenet 2004,
149:98-106.
69. Karan D, Lin FC, Bryan M, Ringel J, Moniaux N, Lin MF, Batra SK:
Expression of ADAMs (a disintegrin and metalloproteases)
and TIMP-3 (tissue inhibitor of metalloproteinase-3) in
human prostatic adenocarcinomas.  Int J Oncol 2003,
23:1365-1371.
70. Nakahara T, Tominaga K, Koseki T, Yamamoto M, Yamato K, Fukuda
J, Nishihara T: Growth/differentiation factor-5 induces growth
arrest and apoptosis in mouse B lineage cells with modula-
tion by Smad.  Cell Signal 2003, 15:181-187.
71. Borlak J, Meier T, Halter R, Spanel R, Spanel-Borowski K: Epidermal
growth factor-induced hepatocellular carcinoma: gene
expression profiles in precursor lesions, early stage and soli-
tary tumours.  Oncogene 2005, 24:1809-1819.
72. Ciccarelli C, Philipson L, Sorrentino V: Regulation of expression
of growth arrest-specific genes in mouse fibroblasts.  Mol Cell
Biol 1990, 10:1525-1529.
73. Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L,
Angel P, Mayer D: Calcium-binding proteins S100A8 and
S100A9 as novel diagnostic markers in human prostate can-
cer.  Clin Cancer Res 2005, 11:5146-5152.
74. Nagaraja GM, Othman M, Fox BP, Alsaber R, Pellegrino CM, Zeng Y,
Khanna R, Tamburini P, Swaroop A, Kandpal RP: Gene expression
signatures and biomarkers of noninvasive and invasive
breast cancer cells: comprehensive profiles by representa-
tional difference analysis, microarrays and proteomics.  Onco-
gene 2006, 25:2328-2338.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/6/105/pre
pub